The U.S. Bankruptcy Court for the Southern District of New York has given Purdue Pharma approval to pay up to $11 million in additional funding to the nonprofit pharmaceutical company Harm Reduction Therapeutics (HRT) to support the development of a low-cost over-the-counter (OTC) naloxone nasal spray.

Since 2018, Purdue had been supplying HRT with funding, technical expertise and has granted access to its data to support its development activities, but the bankruptcy proceedings cut off the funding.

HRT plans to file a New Drug Application for the opioid rescue nasal spray with the FDA this year. Purdue will not receive any revenues, royalties or profits from any sales of the OTC naloxone nasal spray.